Literature DB >> 1915704

The effects of interleukin 6 and interleukin 3 on early hematopoietic events in long-term cultures of human marrow.

T Otsuka1, J D Thacker, D E Hogge.   

Abstract

Interleukin (IL)-6 and IL-3, both alone and in combination, stimulate hematopoietic cells in short-term in vitro assays and in vivo. To study their ability to influence hematopoiesis in a system that mimics many features of the marrow microenvironment, long-term cultures (LTC) were produced by co-cultivating normal human marrow cells on feeder layers of murine marrow-derived stromal cells (M2-10B4 cells) genetically engineered to produce human IL-6 and/or IL-3. Feeders stably producing 20 ng/ml IL-6 slightly increased the output of clonogenic progenitors in these LTC but did not change the production of mature (total nonadherent) cells as compared to control cultures. Feeders producing 50 ng/ml IL-3 increased both clonogenic progenitor output (approximately threefold) and the output of mature cells (six-fold) as compared to controls. Feeders producing both factors also increased the output of both progenitors and mature cells. At the time of the weekly half-medium change when primitive clonogenic progenitors in the adherent layer are quiescent, such progenitors were actively cycling in all cultures with factor-producing feeders, as shown by [3H]thymidine suicide assays. Similarly, three sequential daily additions of 20 ng/ml of IL-6 also stimulated the quiescent progenitors to enter S-phase 2 days later, although single doses of recombinant IL-6 as high as 100 ng/ml failed to do so. The combined presence of IL-6- and IL-3-producing feeders, but neither alone, was also able to enhance more than twofold the maintenance and early differentiation of cells capable of generating clonogenic cells for at least a further 5 weeks in secondary LTC. Thus, the provision of a continuous source of IL-6 or IL-3 to primitive hematopoietic cells even in the LTC system can enhance late events in the hierarchy of hematopoietic cell differentiation, but a combination of the two factors is required to stimulate early multipotent progenitors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1915704

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level.

Authors:  C Udomsakdi; C J Eaves; B Swolin; D S Reid; M J Barnett; A C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

2.  The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.

Authors:  Srinivasan Srirangan; Ernest H Choy
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

3.  Cytokine release by human bone marrow cells: analysis at the single cell level.

Authors:  D Rohde; C Wickenhauser; S Denecke; A Stach; J Lorenzen; M L Hansmann; J Thiele; R Fischer
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.

Authors:  Lomeli R Carpio; Elizabeth W Bradley; Meghan E McGee-Lawrence; Megan M Weivoda; Daniel D Poston; Amel Dudakovic; Ming Xu; Tamar Tchkonia; James L Kirkland; Andre J van Wijnen; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Sci Signal       Date:  2016-08-09       Impact factor: 8.192

5.  Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin.

Authors:  A L Petzer; P W Zandstra; J M Piret; C J Eaves
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

6.  A network pharmacology approach to determine the synergetic mechanisms of herb couple for treating rheumatic arthritis.

Authors:  Xi-Xi Xu; Jian-Ping Bi; Li Ping; Ping Li; Fei Li
Journal:  Drug Des Devel Ther       Date:  2018-04-24       Impact factor: 4.162

Review 7.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.